How to budget an OTC launch in Saudi Arabia
A launch budget is not one number — it is a stack of decisions. How many pharmacies will you list in? How loud will the launch campaign be? Does the category demand heavy sampling, or will the product sell on shelf presence? Each answer moves a bucket, and the buckets add up fast. Building the budget bottom-up — registration, listing, media, sampling, merchandising, creative, and a contingency — forces those decisions into the open before you commit money to them.
The single most useful output is not the total; it is the total relative to your Year-1 sales target. A budget of two million riyals means nothing on its own. As a share of a five-million-riyal sales goal, it is a defensible launch investment. As a share of a one-million-riyal goal, it is a red flag that needs a multi-year business case. That ratio is the conversation to have with finance before, not after, you spend.
Why launches lose money in Year 1 — and that can be fine
Launch investment is front-loaded: you pay to register, list, and advertise before the brand has built any real sell-out. Sales ramp gradually; costs land up front. So most OTC launches break even at best in Year 1, with the return arriving in Years 2 and 3. The mistake is not spending — it is spending without framing the launch as a multi-year bet and without a plan to protect the brand once competitors respond. For the full picture, work through the OTC product launch playbook, and pressure-test the ongoing economics with the CHC contribution margin calculator.
Frequently asked questions
What does it cost to launch an OTC product in Saudi Arabia?
There is no single number — it depends on how many pharmacies you list in, how heavily you advertise, and how much sampling and merchandising the category needs. The major buckets are SFDA registration and regulatory, listing fees (which scale with pharmacy count), launch media, sampling and POSM, field merchandising, and creative and agency costs, plus a contingency. This estimator sums them bottom-up so you see the total before you commit.
What is the investment-to-sales ratio and why does it matter?
It is your total launch budget divided by your Year-1 net sales target. It is the fastest sanity check on a launch plan: it tells you, in one number, how heavily you are investing relative to what you expect to sell. A launch that costs a large share of Year-1 sales is not automatically wrong — but it forces you to justify the spend on a multi-year payback, because Year-1 contribution will not cover it.
Should listing fees scale with the number of pharmacies?
Yes. Listing and slotting costs are largely per-outlet, so the more pharmacies you target, the more you pay to get on shelf. That is why this tool multiplies your per-pharmacy listing fee by your target pharmacy count — expanding distribution is rarely free, and the cost-per-pharmacy metric helps you decide how wide to go at launch.
Why include a contingency line?
Because launches overrun. Regulatory timelines slip, a chain demands an extra activation, print runs get reordered. A contingency of around 10% of the subtotal absorbs the surprises that would otherwise blow the budget. If you have never launched in the market before, lean higher rather than lower.
Does a launch make a profit in Year 1?
Rarely. Launch investment is front-loaded while sales build gradually, so most OTC launches run at a loss or break even at best in Year 1 — the return comes in Years 2 and 3 as the brand establishes. That is exactly why the investment-to-sales ratio matters: it frames the launch as a multi-year bet, not a single-year P&L.
Planning a real launch? The Claude AI Skills Pack includes a Brand Launch Playbook skill that builds the full pre-launch, launch, and post-launch plan around this budget — or join the community to compare launch budgets with other CHC marketers.